The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Aripiprazole (Abilify®) has been rejected for the treatment of moderate to severe manic episodes in bipolar I disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. The review notes that efficacy data are comparisons with placebo rather than active treatments and that the economic case was not sufficiently robust.
Tadafil (Cialis®) 2.5mg and 5mg tablets have been accepted for regular once-daily administration in patients with erectile dysfunction responding to an on-demand regimen of tadalafil who anticipate frequent use (at least twice weekly).
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« New antidepressant class||Tomato-pill for heart disease »|